Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, GW Pharmaceuticals plc (the "Company") issued a press release announcing the Company's preliminary, unaudited net product sales for the fourth quarter and full year 2020 and key priorities for 2021. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



    Number    Description

    99.1        Press release dated January 11, 2021

    104       Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses